CORRECTION OF RETINAL ANGIOPATHY OF HYPERTENSIVE TYPE BY DIMETHYLAMINOETHANOL DERIVATIVE 19-16 IN EXPERIMENT
Introduction: 63% of hypertensive patients have evidence of hypertensive angiopathy. Increase of effectiveness of drug therapy of retinal angiopathy of hypertensive type is an important task of pharmacology.
Objectives: To increase the effectiveness of pharmacological correction of retinal angiopathy of hypertensive type using a new dimethylaminoethanol (DMAE) derivative 19-16.
Materials and methods: We studied protective effects of DMAE derivative 19-16 in doses 25 mg/kg, 50 mg/kg on a model of retinal angiopathy of hypertensive type on Wistar male rats, which was carried out by N-nitro-L-arginine-methyl ester (L-NAME) introducing in a dose 12.5 mg/kg/day within 28 days. To study the fundus of experimental animals, direct ophthalmoscopy was used. Electroretinography (ERG) was recorded in response to a single stimulation. The induced biopotentials were amplified, averaged and presented graphically with the help of Biopac-systems MP-150 with the program AcqKnowledge 4.2 (USA). To assess the degree of development of functional damage to the retina, the ratio of the amplitudes of the b- and a-waves, the coefficient b/a, was estimated.
Results and discussion: DMAE derivative 19-16 in a dose 50 mg/kg prevented the development of ischemic damage and retinal vascular changes caused by introduction of L-NAME, to a greater extent than in a dose 25 mg/kg. The observed retinoprotective effects are confirmed by ophthalmoscopy and ERG.
Conclusion: The search of new ways of correction of the retinal angiopathy as a complication of hypertension is an urgent task of pharmacology, which can be solved by using a new DMAE derivative 19-16.